“TACE抵抗/失败”——需要全面认识  

Comprehensive understanding of the concept and connotation of “TACE-failure/refractoriness”

作　　者：张申 张磊[1] 仲斌演 王万胜[1] 倪才方[1] ZHANG Shen;ZHANG Lei;ZHONG Binyan;WANG Wansheng;NI Caifang(Department of Interventional Radiology,First Affiliated Hospital of Soochow University,Suzhou,Jiangsu Province 215006,China)

机构地区：[1]苏州大学附属第一医院介入科,江苏215006

出　　处：《介入放射学杂志》2020年第8期743-747,共5页Journal of Interventional Radiology

摘　　要：经导管动脉化疗栓塞术(TACE)是公认的中期肝细胞癌(HCC)患者标准治疗方法。然而,由于TACE本身固有的局限性和患者显著的异质性,部分患者存在多次TACE术后肿瘤控制仍然不佳的情况。基于此,近年来"TACE抵抗/失败"的概念备受关注,但有关"TACE抵抗/失败"的定义、内涵存在诸多模糊,甚至矛盾之处。该文就"TACE抵抗/失败"概念、内涵进行解读和分析,试图予以厘清,以更好地对其进行全面与深入的研究,从而进一步提高肝癌治疗效果。Transcatheter arterial chemoembolization(TACE)is the standard strategy for intermediatestage[Barcelona Clinic Liver Cancer(BCLC)stage B]hepatocellular carcinoma(HCC).However,previous evidence showed that due to the inherent limitations of this technique and the vast heterogeneities of the patients,leading to differences in individual response,the efficacy of TACE treatment may be controversial.In this regard,it gave rise to the concept of TACE failure/refractoriness recently.Nevertheless,the definition and intension of TACE failure/refractoriness were confusing and somewhat contradictory.In this review,we aimed to interpret and analyze the concept deeply in order to conduct a comprehensive understanding and prolong the overall survival of HCC patients.

关 键 词：肝细胞癌 经导管动脉化疗栓塞术 失败 抵抗 

分 类 号：R735.7[医药卫生—肿瘤]